Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Website: pfizer.com


  • Bad financial results growth rate -11.2% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-1.7%)
  • Dividend yield for the last twelve months 6.7%
  • Free cash flow yield 9.0% (LTM)
  • Share price is 16.7% higher than minimum and 53.8% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (13.1x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: PFE
Share price, USD:  (+3.9%)25.19
year average price 26.42  


year start price 27.83 2024-07-02

max close price 31.39 2024-07-30

min close price 21.59 2025-04-10

current price 25.19 2025-07-01
Common stocks: 5 615 000 000

Dividend Yield:  6.7%
FCF Yield LTM: 9.0%
EV / LTM EBITDA: 13.1x
EV / EBITDA annualized: 10.3x
Last revenue growth (y/y):  -7.8%
Last growth of EBITDA (y/y):  -14.6%
Historical revenue growth:  -7.3%
Historical growth of EBITDA:  +3.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 141 442
Net Debt ($m): 45 091
EV (Enterprise Value): 186 533
EBITDA LTM ($m): 14 282
EV / LTM EBITDA: 13.1x
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-29prnewswire.com

XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations

2025-06-27zacks.com

PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal

2025-06-25seekingalpha.com

Pfizer Could Be The Turnaround Story In The Pharmaceutical Space

2025-06-25businesswire.com

Pfizer Declares Third-Quarter 2025 Dividend

2025-06-25seekingalpha.com

Don't Sleep On Pfizer: The Turnaround Is Just Getting Started

2025-06-24zacks.com

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

2025-06-20zacks.com

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

2025-06-20seekingalpha.com

Pfizer: An Offensive Play For A Bear Market

2025-06-19247wallst.com

Is It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth Potential

2025-06-19zacks.com

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data